Tove Tuntland
Novartis Institute of Biomedical Research (NIBR), USA
Title: A Modern In Vivo PK Paradigm: Combining Snapshot, Rapid and Full PK Approaches to Support Early Drug Discovery
Biography
Biography: Tove Tuntland
Abstract
Successful drug discovery relies on selection of drug candidates with good in vitro ADME and in vivo pharmacokinetic properties as well as appropriate preclinical efficacy and safety profiles. However, in vivo animal pharmacokinetic studies are often conducted in a traditional low throughput manner, and therefore, are the bottlenecks of discovery projects in many pharmaceutical companies.
This presentation will focus on the tiered in vivo PK approaches, including snapshot PK, rapid PK and full PK study designs we have implemented to support our drug discovery efforts. In all 3 approaches, compound is dosed and analyzed discretely, thereby eliminating any drug-drug interaction concerns and analysis complications typically associated with cassette dosing or cassette analysis. The rapid PK approach uses several integrated and automated processes and sample pooling strategy to improve throughput, and has become our main stream in vivo PK approach in the lead optimization stage. These in vivo PK approaches differ in throughputs, capacities and the resources required, and are designed to address the varying needs of drug discovery projects at different stages of project progression. These approaches are well integrated within discovery research, allow tremendous flexibility and are highly efficient in supporting the diverse needs and increasing demand for in vivo profiling. Examples of each of the tiered in vivo PK studies will be illustrated.